These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 32692127)

  • 1. Two Clinically Important but Underutilized and Misunderstood Tools: Formulas to Estimate Creatinine Clearance and Therapeutic Drug Monitoring.
    Preskorn SH
    J Psychiatr Pract; 2020 Jul; 26(4):305-308. PubMed ID: 32692127
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Practical review of pharmacology concepts.
    Janda SM; Fagan NL
    Urol Nurs; 2010; 30(1):15-20. PubMed ID: 20359141
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Three Clinically Important but Underutilized and Misunderstood Tools: Formulas to Estimate Creatinine Clearance, the Package Insert, and Therapeutic Drug Monitoring.
    Preskorn S
    J Clin Psychiatry; 2019 Nov; 80(6):. PubMed ID: 31774945
    [No Abstract]   [Full Text] [Related]  

  • 4. Using estimated creatinine clearance for individualizing drug therapy: a reassessment.
    Smith CL; Hampton EM
    DICP; 1990 Dec; 24(12):1185-90. PubMed ID: 2089830
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Estimating a drug's elimination rate-constant or half-life from a single blood sample: a practical approach with particular benefits for critically ill/vulnerable patients.
    Scutt G; Allen M; Waxman D
    Biosystems; 2019 Oct; 184():103996. PubMed ID: 31369834
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Pharmacokinetic bases of dosage adaptation of drugs in renal insufficiency].
    Lesne M
    J Pharm Belg; 1988; 43(3):212-32. PubMed ID: 3171871
    [No Abstract]   [Full Text] [Related]  

  • 7. Basic principles of pharmacologic action.
    Schwertz DW
    Nurs Clin North Am; 1991 Jun; 26(2):245-62. PubMed ID: 2047284
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Estimation of creatinine clearance.
    Jelliffe R
    J Clin Pharmacol; 2008 Oct; 48(10):1242-4; author reply 1244. PubMed ID: 18812612
    [No Abstract]   [Full Text] [Related]  

  • 9. Developmental Changes in Pharmacokinetics and Pharmacodynamics.
    van den Anker J; Reed MD; Allegaert K; Kearns GL
    J Clin Pharmacol; 2018 Oct; 58 Suppl 10():S10-S25. PubMed ID: 30248190
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum cystatin C-based equation compared to serum creatinine-based equations for estimation of glomerular filtration rate in patients with chronic kidney disease.
    Hojs R; Bevc S; Ekart R; Gorenjak M; Puklavec L
    Clin Nephrol; 2008 Jul; 70(1):10-7. PubMed ID: 18793543
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug dosage in renal disease.
    Dettli L
    Clin Pharmacokinet; 1976; 1(2):126-34. PubMed ID: 797495
    [TBL] [Abstract][Full Text] [Related]  

  • 12. How pharmacogenomics (PG) are changing practice: implications for prescribers, their patients, and the healthcare system (PG series part I).
    Preskorn SH; Hatt CR
    J Psychiatr Pract; 2013 Mar; 19(2):142-9. PubMed ID: 23507814
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Amikacin pharmacokinetics: wide interpatient variation in 98 patients.
    Zaske DE; Strate RG; Kohls PR
    J Clin Pharmacol; 1991 Feb; 31(2):158-63. PubMed ID: 2010561
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Monitoring of therapy using drug concentration levels: Why? When? How?].
    Vozeh S
    Ther Umsch; 1990 Aug; 47(8):635-9. PubMed ID: 2218964
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regulatory perspectives on designing pharmacokinetic studies and optimizing labeling recommendations for patients with chronic kidney disease.
    Zhang L; Xu N; Xiao S; Arya V; Zhao P; Lesko LJ; Huang SM
    J Clin Pharmacol; 2012 Jan; 52(1 Suppl):79S-90S. PubMed ID: 22232757
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Augmented Renal Clearance.
    Cook AM; Hatton-Kolpek J
    Pharmacotherapy; 2019 Mar; 39(3):346-354. PubMed ID: 30723936
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dose size and dosing interval determination.
    Ritschel WA
    Arzneimittelforschung; 1975 Sep; 25(9):1442-7. PubMed ID: 1242670
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Safe drug prescribing for patients with renal failure].
    Tanaka A; Shimizu H; Matsuo S
    Nihon Rinsho; 2007 Oct; 65 Suppl 8():58-66. PubMed ID: 18074518
    [No Abstract]   [Full Text] [Related]  

  • 19. Principles and clinical application of assessing alterations in renal elimination pathways.
    Tett SE; Kirkpatrick CM; Gross AS; McLachlan AJ
    Clin Pharmacokinet; 2003; 42(14):1193-211. PubMed ID: 14606929
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The use of marker drugs to measure organ function: a theoretical interpretation.
    Cobby J; Makoid MC
    Eur J Clin Pharmacol; 1980 Nov; 18(6):511-6. PubMed ID: 7461018
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.